Our research group aims to develop antiviral strategies against (re)emerging viruses, including novel host-directed approaches. We primarily study mosquito-borne alphaviruses and flaviviruses—such as chikungunya, Zika, and West Nile virus— but since the pandemic, we have expanded our research to encompass SARS-CoV-2, with a focus on antivirals and vaccine development.
